• GATEWAY, VTX-801 Phase 1/2 Study for Wilson Disease

    GATEWAY, VTX-801 Phase 1/2 Study for Wilson Disease
    Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

     Read More
  • Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation

    VTX-803 receives US & EU ODD
    Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation

     Read More
  • Wilson disease

    Wilson disease
    Benefits of AAV gene therapy as a novel approach to manage Wilson disease

     Read More
Gene Therapy Programs Gene Therapy Programs

A dedicated platform for the development of innovative treatments for inherited liver diseases in partnership with FIMA
Product Pipeline Product Pipeline

Targeting life threatening and severely debilitating liver metabolic disorders with high unmet medical need in pediatric and adult patients
Wilson disease Wilson disease

Development of a high-activity ATP7B transgene paves the way towards restoring normal copper metabolism in Wilson disease patients through gene therapy

Welcome to Vivet Therapeutics

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.

Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra)  to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Latest News